Top

Published in:

01-05-2012 | Original Article

Increased CD133 expression after preoperative chemoradiotherapy in rectal cancers other than mucin-rich tumors

Authors: Chih-Hung Lin, Wan-Tzu Chen, Chia-Hsing Liu, Hung-Pei Tsai, Chun-Chieh Wu, Chee-Yin Chai

Published in: Virchows Archiv | Issue 5/2012

Abstract

This study is to characterize the sequential change in CD133 expression after preoperative chemoradiotherapy (CRT) in rectal cancer and its impact on postoperative prognosis. Forty-one patients with rectal cancer who had received CRT before surgery were selected retrospectively. In each case, immunohistochemical analysis was performed to compare CD133 expression in biopsy specimens taken before and after CRT. After CRT, CD133 expression was significantly increased in 14 (34%) patients, mildly increased in 25 (61%), and decreased in 2 (5%). However, no mucin-rich tumors showed high CD133 expression before or after CRT (p < 0.001). Disease-free survival and overall survival were significantly poorer in patients with significantly increased CD133 (p = 0.049 and p = 0.038, respectively). Increased CD133 after CRT is a significant prognostic factor in rectal cancer patients treated with preoperative CRT and surgical resection. CD133 might be an essential cancer stem cell marker.

Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760PubMedCrossRef

Jordan CT, Guzman ML, Noble M (2006) Cancer stem cells. N Engl J Med 355:1253–1261PubMedCrossRef

O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110PubMedCrossRef

Todaro M, Francipane MG, Medema JP, Stassi G (2010) Colon cancer stem cells: promise of targeted therapy. Gastroenterology 138:2151–2162PubMedCrossRef

Ward RJ, Dirks PB (2007) Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol 2:175–189PubMedCrossRef

Horst D, Kriegl L, Engel J, Kirchner T, Jung A (2008) CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99:1285–1289PubMedCrossRef

Horst D, Kriegl L, Engel J, Kirchner T, Jung A (2009) Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 27:844–850PubMedCrossRef

Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115PubMedCrossRef

Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Kawamoto A, Yasuda H, Morimoto Y, Fujikawa H, Inoue Y, Miki C, Kusunoki M (2010) Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer. Oncol Rep 24:345–350PubMedCrossRef

10.

Deng YH, Pu XX, Pu MJ, Huang JX, Zhou JM, Lin TY, Lin EH (2010) 5-Fluorouracil up regulates the activity of Wnt signaling pathway in CD133-positive colon cancer stem-like cells. Chin J Cancer 29:810–815PubMed

11.

Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R, Salto-Tellez M (2010) CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol 23:450–457PubMedCrossRef

12.

Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Koike Y, Fujikawa H, Inoue Y, Miki C, Kusunoki M (2011) Clinical significance of CD133 and hypoxia inducible factor-1alpha gene expression in rectal cancer after preoperative chemoradiotherapy. Clin Oncol (R Coll Radiol) 23:323–332CrossRef

13.

Haraguchi N, Ohkuma M, Sakashita H, Matsuzaki S, Tanaka F, Mimori K, Kamohara Y, Inoue H, Mori M (2008) CD133+ CD44+ population efficiently enriches colon cancer initiating cells. Ann Surg Oncol 15:2927–2933PubMedCrossRef

14.

Nakamura K, Iinuma H, Aoyagi Y, Shibuya H, Watanabe T (2010) Predictive value of cancer stem-like cells and cancer-associated genetic markers for peritoneal recurrence of colorectal cancer in patients after curative surgery. Oncology 78:309–315PubMedCrossRef

15.

Xi HQ, Zhao P (2011) Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol 64:498–503PubMedCrossRef

16.

Kojima M, Ishii G, Atsumi N, Nishizawa Y, Saito N, Ochiai A (2010) CD133 expression in rectal cancer after preoperative chemoradiotherapy. Cancer Sci 101:906–912PubMedCrossRef

17.

Tentes IK, Schmidt WM, Krupitza G, Steger GG, Mikulits W, Kortsaris A, Mader RM (2010) Long-term persistence of acquired resistance to 5-fluorouracil in the colon cancer cell line SW620. Exp Cell Res 316:3172–3181PubMedCrossRef

18.

Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A (2008) Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 99:1578–1583PubMedCrossRef

19.

Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, Miki C, Kusunoki M (2009) Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 16:3488–3498PubMedCrossRef

20.

Shimizu K, Itoh T, Shimizu M, Ku Y, Hori Y (2009) CD133 expression pattern distinguishes intraductal papillary mucinous neoplasms from ductal adenocarcinomas of the pancreas. Pancreas 38:e207–e214PubMedCrossRef

21.

Wang YK, Zhu YL, Qiu FM, Zhang T, Chen ZG, Zheng S, Huang J (2010) Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. Carcinogenesis 31:1376–1380PubMedCrossRef

22.

Dong TT, Zhou HM, Wang LL, Feng B, Lv B, Zheng MH (2011) Salinomycin selectively targets ‘CD133 +’ cell subpopulations and decreases malignant traits in colorectal cancer lines. Ann Surg Oncol 18:1797–1804PubMedCrossRef

Title: Increased CD133 expression after preoperative chemoradiotherapy in rectal cancers other than mucin-rich tumors
Authors: Chih-Hung Lin
Wan-Tzu Chen
Chia-Hsing Liu
Hung-Pei Tsai
Chun-Chieh Wu
Chee-Yin Chai
Publication date: 01-05-2012
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 5/2012
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-012-1210-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Increased CD133 expression after preoperative chemoradiotherapy in rectal cancers other than mucin-rich tumors

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2012

Erratum to: Immortalized bovine pancreatic duct cells become tumorigenic after transfection with mutant k-ras

Erratum to: Gene expression profiles of microdissected pancreatic ductal adenocarcinoma

Nonsebaceous lymphadenoma of salivary glands: proposed development from intraparotid lymph nodes and risk of misdiagnosis

NSCLC and the alternative pathway of NF-κB: uncovering an unknown relation

Loss of heterozygosity on chromosome 16q suggests malignancy in core needle biopsy specimens of intraductal papillary breast lesions

An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer